Author
@FierceBiotech FierceBiotech
Biotech trade-press outlet breaking trial, deal, and FDA news with clinical context
Report original biotech/pharma industry news — clinical read
trader score
-0.83
hit rate
33%
mean α
-1.85%
signals 14d
16
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 9 scored bets: 33% hit rate, -1.85% mean alpha, trader score -0.83. Their last-14d mentions, direction-adjusted, have moved -1.5% since posting (mean over 5 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-15 | · | @FierceBiotech | · | OrbiMed raised $3 billion for life-sciences investments, including over $1 billion for Asia. | · | tweet ↗ |
| 2026-10-15 | · | @FierceBiotech | · | Private biotech OMass Therapeutics secured $310 million in fresh funding. | · | tweet ↗ |
| 2026-10-14 | · | @FierceBiotech | · | Private Verdiva Bio scrapped a phase 2 trial of oral GLP-1 candidate VRB-101. | · | tweet ↗ |
| 2026-10-14 | · | @FierceBiotech | · | Zealand signed a $1.2B pact with private Generate to add multispecific proteins to its obesity pipeline. | · | tweet ↗ |
| 2026-10-14 | VIR | @FierceBiotech | +0.35 | Gilead licensed Vir Biotechnology's T-cell engager technology in a potential $1.9B deal. | · | tweet ↗ |
| 2026-10-14 | GILD | @FierceBiotech | +0.15 | Gilead licensed Vir Biotechnology's T-cell engager technology in a potential $1.9B deal. | +1.6% | tweet ↗ |
| 2026-10-08 | RHHBY | @FierceBiotech | -0.20 | Blood-sugar data weakened enthusiasm for Zealand and Roche's amylin obesity drug. | +14.6% | tweet ↗ |
| 2026-10-08 | ZEAL | @FierceBiotech | -0.35 | Blood-sugar data weakened enthusiasm for Zealand and Roche's amylin obesity drug. | · | tweet ↗ |
| 2026-10-08 | · | @FierceBiotech | · | A phase 2b readout suggests Endeavor's drug may reduce fibrosis and increase lung capacity. | · | tweet ↗ |
| 2026-10-07 | · | @FierceBiotech | · | Matchpoint Therapeutics raises $150M in Series B financing to advance its pipeline. | · | tweet ↗ |
| 2026-10-07 | · | @FierceBiotech | · | Atsena reports efficacy evidence and plans an approval-supporting study for 2028. | · | tweet ↗ |
| 2026-10-07 | · | @FierceBiotech | · | An unidentified biotech ends all clinical development and announces a substantial workforce reduction. | · | tweet ↗ |
| 2026-10-05 | PFE | @FierceBiotech | +0.00 | Reports Vaxcyte stock jumping after a phase 3 head-to-head vaccine contest. | +9.6% | tweet ↗ |
| 2026-10-05 | PCVX | @FierceBiotech | +0.55 | Reports Vaxcyte stock jumping after a phase 3 head-to-head vaccine contest. | · | tweet ↗ |
| 2026-10-05 | MRK | @FierceBiotech | +0.00 | Reports Vaxcyte stock jumping after a phase 3 head-to-head vaccine contest. | +4.1% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.